![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2023/01/23/2593058/0/en/OncXerna-Therapeutics-Announces-Final-Results-and-New-Xerna-TME-Panel-Biomarker-Data-from-a-Phase-2-Trial-of-Bavituximab-Plus-Pembrolizumab-in-Patients-with-Previously-Untreated-Ad.html
https://www.globenewswire.com/news-release/2022/09/12/2513841/0/en/OncXerna-Therapeutics-Announces-New-Xerna-TME-Panel-Biomarker-Data-from-Retrospective-Analysis-of-Results-from-a-Randomized-Phase-2-Trial-Evaluating-Anti-PD-1-Maintenance-Therapy-i.html
https://www.clinicaltrialsarena.com/news/oncxerna-subject-navicixizumab-trial/
https://www.globenewswire.com/news-release/2022/09/08/2512403/0/en/OncXerna-Therapeutics-Doses-First-Patient-in-Phase-2-Trial-Evaluating-Navicixizumab-Alone-or-in-Combination-with-Chemotherapy-in-Patients-with-Select-Advanced-Solid-Tumors.html
https://www.globenewswire.com/news-release/2022/06/03/2455957/0/en/OncXerna-Therapeutics-Announces-Upcoming-ASCO-Poster-Featuring-Data-Showing-the-Phase-2-Glioblastoma-Trial-of-Bavituximab-with-Chemoradiation-and-Adjuvant-Temozolomide-Met-its-Prim.html